AbbVie Files Patent Suit Over Amgen's Copy of Humira
August 05 2016 - 2:33PM
Dow Jones News
By Jonathan D. Rockoff
Drugmaker AbbVie Inc. has filed a patent-infringement lawsuit
against rival Amgen Inc. seeking to halt looming sales of a
lower-priced replica of AbbVie's top-selling drug, Humira.
The lawsuit, filed late Thursday in federal court in Delaware,
alleges Amgen's copy of Humira violates many of AbbVie's patents on
the anti-inflammatory treatment. The suit asks the court to block
any sales.
Humira accounts for about 60% of AbbVie's revenue. AbbVie has
been taking steps, including filing new patents protecting Humira,
to delay the introduction of copies, and has told analysts it
expects copies to hit the market no earlier than 2022.
AbbVie's legal challenge was an expected step, which was
authorized under the federal law that aimed to bring price
competition to expensive biotech drugs. Copies of these drugs are
known as biosimilars.
The law, the Biosimilar Price Competition and Innovation Act,
established a mechanism for companies to secure approval of biotech
drug copies without doing all the testing a new medicine would
require.
In its lawsuit, AbbVie said the law "does not give Amgen license
to infringe AbbVie's patents." AbbVie also threatened further
patent infringement suits because it claims 61 Humira patents are
being infringed.
Humira is one of the top-selling drugs in the U.S., with $8.4
billion in sales last year. It is also expensive, with a list price
of $53,260 a year.
Biosimilars were authorized as part of the 2009 federal
health-care overhaul to reduce spending on such biotech drugs, much
like generics have cut the costs of pills.
Given Humira's success, several drug companies have been
developing biosimilar versions. Amgen already sells a brand-name
rival, Enbrel.
The Food and Drug Administration hasn't approved Amgen's
biosimilar Humira yet, but the decision is nearing. Last month, a
panel of outside experts recommended approval.
Amgen said Friday it doesn't comment on litigation, but that it
is working with the FDA as the agency completes its review of the
company's biosimilar Humira.
The patent-infringement challenge is likely to delay launch of
Amgen's biosimilar, if it is approved, until the legal issues are
resolved. Launch could be delayed even further if AbbVie decides to
file another infringement lawsuit involving additional patents,
after an FDA decision on approving the biosimilar.
A litigation delay followed the approval last year of the first
biosimilar, Novartis AG's Zarxio, which was a replica of an Amgen
cancer-care drug called Neupogen.
As a result, Zarxio, which was approved in March 2015, didn't go
on sale until September. Novartis sold its drug at a 15% discount
to the original.
This week, CVS Health Corp., whose Caremark unit administers
drug benefits for many employers and insurers, took steps to start
steering patients to biosimilars.
Write to Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com
(END) Dow Jones Newswires
August 05, 2016 14:18 ET (18:18 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024